Topics:

Breast Cancer

Management of Young Breast Cancer Patients With de Novo Genetic Mutations

A 24-year-old woman presents to her primary care provider with a mass in her left breast. Examination confirms a 2.2-cm mass in the upper outer quadrant, with a single mobile axillary node that is firm to palpation.

Breast Cancer

The use of tumor genome profiling to identify actionable or targetable mutations in women with breast cancer is not ready for routine use in clinical practice.

The risk of early, sudden-onset menopause in women treated for early-stage breast cancer can be reduced with goserelin, a gonadotropin-releasing hormone agonist.

Localized correlated spectroscopy may show signs of biochemical abnormalities, possibly signaling breast cancer among women with BRCA gene.

As more treatment options become available for metastatic HER2-positive breast cancer, some questions regarding the optimal sequencing of therapies remain.

The idea that breast cancer is overdiagnosed is being perpetuated in an effort to reduce access to breast cancer screening, according to a presentation at MBCC.

Breast density awareness is more common in women who are educated, had higher household income, and have health insurance.

In this video from MBCC we discuss a poster presentation on genomic and protein alterations in 126 triple-negative metaplastic breast cancers.

Pages

Subscribe to Breast Cancer on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.